Get Help Now

Whether you’re ready to start your journey with EHN Canada now or just want to learn more, our admissions counsellors can guide you through your options.

EHN Canada

1-416-644-6345

Not quite sure? Chat with a live consultant.

EHN Canada

Resources

Psychedelics in the Treatment of Substance Use Disorders

Eligible CEU Credits
CACCF: 1 credits
MDPAC: 1 credits
CCPA: 1 credits
CVRP: 1 credits
HRPA: 0 credits
CPHR BC & Yukon: 0 credits
CPHR Alberta: 0 credits
CPHR Manitoba: 0 credits
CPHR Nova Scotia: 0 credits

With Dr. Ian King, BMSc, MD, FRCPC, DRCPSC (Addiction Medicine),

Psychiatrist, Edgewood Treatment Centre

Studies on the effectiveness of psychedelics in the treatment of addiction and psychosis is still very limited in size and methodological quality. Nevertheless, most studies show positive effects of both classical and atypical psychedelics in a variety of addictions on motivation, craving, reduced consumption, and abstinence often following a single dose and with long-lasting benefits (3-24 months). Join Dr. Ian King, Psychiatrist at Edgewood Treatment Centre, on Thursday, October 20 between 12-1pm EST as he explains the background of psychedelics as a class of substances and to examine current evidence supporting the use of psychedelics in treating substance use disorder.

LEARNING OBJECTIVES:

  • Understand the background on psychedelics as a class of substances, including historical context in culture and research
  • Review basic pharmacological actions of psychedelics and the proposed neural targets and mechanisms in treating substance use disorders
  • Summarize and appraise the current evidence supporting the use of psychedelics in treating substance use disorders

Date: October 20, 2022 – 12pm ET, 9am PT

Duration: 1-hour (45-minute presentation followed by a 15-minute Q&A)

Cost: COMPLIMENTARY

This webinar provides 1.0 CEU credits recognized by the CACCF, CCPA, MDPAC, and CVRP.

The content presented in this webinar was accurate at time of broadcast.